Andrew Gengos - 22 Feb 2022 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Reporting relationship: Chief Business Officer
Issuer ticker: N/A
Reported as of: 22 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Feb 2022, 15:57:18 UTC
Prior SEC filing: 17 Jun 2021
Next SEC filing: 22 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Andrew Gengos

Key filing fact

Andrew Gengos filed Form 4 for Cyteir Therapeutics, Inc. on 24 Feb 2022.

Key facts

This page summarizes Andrew Gengos's Form 4 filing for Cyteir Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Feb 2022, 15:57.

Change

Previous filing in this sequence was filed on 17 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CYT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +35,000
Change %
Price: $0.000000
Shares after: 35,000
Date: 22 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,000
Exercise price: $5.96
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.